Document is current
Any future updates will be listed below
-
Authors
Gonzalez, Brian D. https://orcid.org/0000-0001-5108-5735
Eisel, Sarah L.
Qin, Bo
Llanos, Adana A. M.
Savard, Josée
Hoogland, Aasha I.
Jim, Heather
Lin, Yong
Demissie, Kitaw
Hong, Chi-Chen
Bandera, Elisa V.
-
Funding
Funding for this research was provided by:
National Cancer Institute (K01 CA211789)
National Cancer Institute (K01 CA193527)
National Cancer Institute (K99 MD013300)
National Cancer Institute (R01 CA185623)
National Cancer Institute (P01 CA151135)
National Cancer Institute (R25 CA090314)
National Cancer Institute (P30 CA016056)
National Cancer Institute (HHSN261201300021I)
National Heart, Lung, and Blood Institute (R25 HL105444)
National Cancer Institute (R01 CA185623S1)
National Cancer Institute (P30 CA072720-5929)
Breast Cancer Research Foundation
Centers for Disease Control and Prevention (NU5U58DP003931-05-00)
- License Information
-
More Information
Article History
Received: 7 May 2020
Accepted: 16 September 2020
First Online: 29 September 2020
Compliance with ethical standards
:
: HJ: Red Hill Biopharma, Janssen Scientific Affairs. BG: SureMed Compliance, Elly Health. All the other authors declare that they have no conflict of interest.
: The study protocol (ID no. Pro2017000069) was approved by the Institutional Review Board at Rutgers, The State University of New Jersey, and Roswell Park Comprehensive Cancer Center.
: All participants provided written informed consent before participating.
: All authors have consented to publishing this manuscript.
: The codes that support the findings of this study are available on request from the corresponding author.
